% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • trade2win87 trade2win87 Apr 12, 2013 8:41 AM Flag

    Belviq is competing against the anti-obesity drug Qsymia

    Belviq is competing against the anti-obesity drug Qsymia, which is also available. Lief isn't bothered by that. "No single drug is sufficient for all indications, so I think the market is quite large," he said. "Obesity or people who are overweight account for about half of the adult population, so I think we'll have a very, very good opportunity," Lief said.

    (Watch: No Dent in Sales on Economic Uncertainties)

    To better market Belviq, Arena has partnered with Eisai, the Japanese company best known for producing Aricept, the $2 billion Alzheimer's drug still used today, and gastrointestinal drug Aciphex.

    "They have about 10 drugs that they've been successful with, and we look forward to Belviq being quite successful, too," Lief said.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.71+0.06(+3.64%)Jun 28 4:00 PMEDT